Parexel
Financials
Estimates*
EUR | 2015 |
---|---|
R&D budget | 22.0m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | - | ||
* | N/A | - | |
$8.5b Valuation: $8.5b | Buyout | ||
Total Funding | - |
Related Content
Recent News about Parexel
EditParexel is a leading clinical research organization (CRO) that specializes in providing a full range of Phase I to IV clinical development services. The company operates in the pharmaceutical and biotechnology sectors, primarily serving clients who are developing new treatments and therapies. Parexel's business model revolves around offering end-to-end clinical trial management, regulatory consulting, and biostatistical analysis to ensure the efficient and effective development of new drugs. The company generates revenue through service contracts with pharmaceutical companies, biotech firms, and medical device manufacturers. Parexel is recognized for its expertise, quality, and reliability, having received multiple industry awards. The company is also committed to advancing gender partnership and leadership within its organization.
Keywords: clinical research, Phase I-IV trials, regulatory consulting, biostatistics, pharmaceutical, biotechnology, drug development, patient-centric, CRO, life sciences.